Stevens-Johnson syndrome associated with Malarone antimalarial prophylaxis.
To the best of our knowledge, Stevens-Johnson syndrome (SJS) has not been reported previously as an adverse reaction to Malarone, which is a combination of atovaquone and proguanil hydrochloride used for antimalarial prophylaxis and therapy. We describe a 65-year-old patient who had SJS with typical clinical and histopathological findings associated with the use of Malarone prophylaxis for malaria. This report should alert physicians to this severe cutaneous reaction, and Malarone should be added to the list of drugs that can potentially cause SJS.
Emberger
Michael
M
Department of Dermatology, General Hospital Salzburg, 5020 Salzburg, Austria. M.Emberger@lks.at
Lechner
Arno Michael
AM
Zelger
Bernhard
B
D000368:Aged; D000818:Animals; D000962:Antimalarials / Q000009:adverse effects*; D053626:Atovaquone; D018890:Chemoprevention; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D009285:Naphthoquinones / Q000009:adverse effects*; D002727:Proguanil / Q000009:adverse effects*; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced*
D000962:Antimalarials; D004338:Drug Combinations; D009285:Naphthoquinones; C109496:atovaquone, proguanil drug combination; D002727:Proguanil; D053626:Atovaquone